GuideAI Health Corp. Announces Closing of Business Combination, Subscription Receipt Offering, and Filing of Final Prospectus

GuideAI Health Corp. has successfully completed its business combination with GuideAI Health, Inc., a transaction valued at $5.15 million, as announced on June 16, 2026. This strategic move was executed through a plan of arrangement under the Business Corporations Act of British Columbia, wherein a wholly-owned subsidiary of GuideAI Health Corp. acquired all outstanding securities of GuideAI Health, Inc. In conjunction with this transaction, the company has filed a final non-offering prospectus for a subscription receipt offering, which includes the issuance of 5,150,000 subscription receipts priced at $1.00 each.

The completion of this business combination marks a pivotal moment for GuideAI Health Corp., which has now rebranded from its previous designation as 1532139 B.C. Ltd. The newly formed entity aims to leverage artificial intelligence to enhance the detection and management of vascular and cardiovascular diseases. The leadership team, including Chief Executive Officer Raj Shah and Chief Medical Officer Luke Higgins, emphasizes their commitment to making advanced healthcare technology accessible to a broader range of providers, beyond just major academic centers. This aligns with the growing trend in healthcare towards integrating AI solutions to improve patient outcomes.

The transaction also included a brokered private placement that raised gross proceeds of $5.15 million, which will be utilized to further the company's mission. Each subscription receipt will convert into one common share upon meeting specific escrow release conditions. The offering was facilitated by Research Capital Corporation, which acted as the agent, and received a fee structure that includes a 2% advisory fee and options for future share purchases. This financing is expected to provide the necessary capital to scale operations and enhance clinical impact in the healthcare sector.

The approval for listing common shares on Cboe Canada is currently conditional, pending the fulfillment of standard regulatory requirements. The transaction not only signifies a strategic consolidation in the healthcare technology sector but also reflects a broader trend of increasing investment in AI-driven solutions within the industry. As healthcare providers seek innovative ways to improve efficiency and patient care, the integration of AI technologies is likely to become a focal point for future investments and partnerships.

Overall, the successful completion of GuideAI Health Corp.'s business combination is indicative of the growing intersection between healthcare and technology. As the demand for advanced healthcare solutions continues to rise, companies like GuideAI Health Corp. are well-positioned to capitalize on this trend, potentially reshaping the landscape of vascular and cardiovascular disease management. The implications of this transaction may resonate throughout the healthcare sector, encouraging further investments and collaborations aimed at harnessing the power of artificial intelligence to address pressing healthcare challenges.